Format

Send to

Choose Destination
AIDS. 2017 Jan 2;31(1):171-173.

Immune activation, smoking, and vaccine response.

Author information

1
aInstitute of Human Genetics, CNRS UPR1142, Montpellier, France bINSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universités, UPMC Paris 06 cAssistance Publique Hôpitaux de Paris (AP-HP), Public Health Unit, Hôpital Saint-Antoine dSorbonne Paris Cité, AP-HP, CIC Cochin Pasteur, Hôpital Cochin, Université Paris Descartes, Paris eInserm, F-CRIN, I-REIVAC, Paris fMontpellier University, Montpellier gImmunology Department, University Hospital, Nîmes, France. *Study group members are listed after the text. †OL and PC contributed equally to this work.

Abstract

Here, we tested the hypothesis that chronic immune activation might fuel interindividual variability in vaccine response in the model of hepatitis B virus vaccine in HIV-1-infected adults. We observed that the marker of inflammation soluble tumour necrosis factor receptor I (sTNFRI) is predictive for vaccine efficiency. We also established that the link between tobacco smoking and impaired vaccine response might be mediated by inflammation. These data are a step forward in personalized vaccination.

PMID:
27835620
DOI:
10.1097/QAD.0000000000001311
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center